{"id":"NCT00560950","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)","officialTitle":"A Multicenter, Open-Label Study of the Safety, Tolerability, and Immunogenicity of Revaccination With PNEUMOVAX(TM) 23 Vaccine (Pneumococcal Vaccine Polyvalent, Merck & Co., Inc.) in Older Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2008-05","completion":"2008-05","firstPosted":"2007-11-20","resultsPosted":"2009-05-25","lastUpdate":"2017-04-11"},"enrollment":143,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infection"],"interventions":[{"type":"BIOLOGICAL","name":"pneumococcal 23v polysaccharide vaccine","otherNames":["V110","PNEUMOVAX"]}],"arms":[{"label":"1st Revaccination Group","type":"EXPERIMENTAL"},{"label":"2nd Revaccination Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine that revaccination of Pneumococcal Vaccine is well tolerated and produces an immune response in older adults.","primaryOutcome":{"measure":"Geometric Mean Concentration for Prevaccination (Day 1) to Postvaccination (Day 30) During the Extension Phase Subjects Completing the Extension for Serotype 3","timeFrame":"Day 1 & Day 30","effectByArm":[{"arm":"1st Revaccination Group Day 1","deltaMin":0.6,"sd":null},{"arm":"1st Revaccination Group Day 30","deltaMin":1.4,"sd":null},{"arm":"2nd Revaccination Group Day 1","deltaMin":0.7,"sd":null},{"arm":"2nd Revaccination Group Day 30","deltaMin":1.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"59 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21860256","20088694"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Pain (Injection site)","Fatigue","Pain","Swelling","Erythema"]}}